PHMB-Impregnated Acellular Biologic Grafts for Treatment of Third-Degree Burns

PHMB 浸渍的脱细胞生物移植物用于治疗三度烧伤

• 批准号: 10338915
• 负责人: Nicholas Pashos
• 金额: $ 5.2万
• 依托单位: BIOAESTHETICS CORPORATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-18 至 2021-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10338915
• 关键词: Affect; Anti-Infective Agents; Antibiotics; Biological; Burn injury; Cessation of life; Clinical; Contracts; Drug resistance; Ecosystem; Enrollment; Goals; Grant; Health; Health Care Costs; Hospitalization; Hospitals; Infection; Infection prevention; Injury; Innovation Corps; Insurance Carriers; Legal patent; Length of Stay; Link; Medical; Operative Surgical Procedures; Patients; Pharmaceutical Preparations; Phase; Polymers; Price; Quality of life; Recovery of Function; Reporting; Risk; Site; Small Business Technology Transfer Research; Technology; Testing; Time; Tissue Grafts; Tissues; Training; Treatment Cost; United States National Institutes of Health; Work; antimicrobial; burn therapy; burn wound; commercialization; healing; health care service utilization; improved; in vivo; innovation; novel; pathogen; preference; programs; reconstruction; regenerative; scaffold; severe burns; third degree burn; wound; wound closure; wound healing

PROJECT SUMMARY BioAesthetics is developing a novel acellular graft for improved burn wound healing. Our patent- pending drug-loaded, polymer-integrated acellular biologic graft (PCT/US19/25306) will act as a barrier to pathogens, deliver anti-infectives to the wound site during healing, and provide an optimal regenerative scaffold. This will allow for a single-stage wound reconstruction, without the need for additional patient-derived tissue, of full-thickness burns (e.g., second- and third-degree burns). Our predicate STTR Phase 1 grant is geared towards providing proof-of-concept that our grafts are capable of promoting wound healing and preventing infection in burn wounds in vivo. The goal of this proposal is to enroll in the NIH I-corps program, which will help BioAesthetics validate customer needs and commercialize this technology. Our objective within the NIH I-corps program is to understand the larger ecosystem surrounding tissue graft use, including clinician product preference in treatment of burns, pricing and reimbursement through hospitals and insurer networks, and antimicrobial use. In the US, burns requiring medical treatment affect nearly 500,000 people each year, causing approximately 40,000 hospitalizations and 3,400 deaths. A 2010 Healthcare Cost and Utilization Project brief reported that approximately $1.5B was spent in the US on burn-related injuries, with an additional $5B linked to lost work. Many clinical challenges exist related to burn treatment including infection, time to wound closure, and time to functional recovery, which can result in long hospital stays, high treatment costs, and an increased risk of contracting a drug-resistant infection. There is a significant unmet need to identify novel, innovative approaches to safely treat patients with serious burn wounds. We believe that our enhanced acellular graft will be able to rapidly heal infected burn wounds, reduce the need for antibiotics, not require additional surgeries, and improve patient quality of life.

项目摘要 Bioaesthetics正在开发一种新型的细胞移植物，以改善烧伤伤口愈合。我们的专利 - 待处理的药物，聚合物集成的细胞生物移植（PCT/US19/25306）将充当 病原体的障碍，在愈合过程中向伤口部位输送抗感染物，并提供 最佳再生支架。这将允许单级伤口重建，而没有 需要额外的患者衍生组织，全厚度燃烧（例如，二级和三级 烧伤）。我们的谓词STTR阶段1赠款旨在提供概念证明 移植物能够促进伤口愈合并防止体内烧伤伤口的感染。 该提案的目的是参加NIH I-Corps计划，这将有助于生物学 验证客户需求并商业化这项技术。我们在NIH I-Corps中的目标 程序是了解组织移植物周围更大的生态系统，包括临床医生 通过医院和 保险公司网络和抗菌使用。在美国，需要治疗的烧伤几乎影响 每年50万人，大约40,000例住院和3,400人死亡。一个 2010年医疗保健成本和利用率项目简介报告说，花费了约1.5b美元 在美国，与烧伤有关的伤害，额外的$ 5B与损失的工作有关。许多临床 存在与烧伤治疗有关的挑战，包括感染，伤口闭合时间以及时间 功能恢复，这可能导致长期住院，高治疗费用和增加 患有耐药感染的风险。识别小说有很大的未满足需求 创新的方法可以安全地治疗严重烧伤的患者。我们相信我们的 增强的细胞移植物将能够快速治愈感染的烧伤伤口，减少对 抗生素，不需要额外的手术并改善患者的生活质量。